Cite

    Ankita Patel et al.. “Outcomes of de novo belatacept‐based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization.” Nephrology, vol. 27, no. 11, 2022, pp. 901–905. http://access.bl.uk/ark:/81055/vdc_100167906770.0x00002f